deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT02013219

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor: Hoffmann-La Roche

Conditions Non-Small Cell Lung Cancer
Interventions Alectinib Atezolizumab Erlotinib
Updated 18 times since 2017 Last updated: Apr 17, 2020 Started: Apr 3, 2014 Primary completion: Feb 5, 2020 Completion: Feb 5, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non-Small Cell Lung Cancer and is currently completed. Hoffmann-La Roche leads this study, which shows 18 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Dec 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Oct 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  11. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Chicago, United States , Cleveland, United States , Detroit, United States , London, United Kingdom , Madrid, Spain , New Haven, United States , New York, United States , Orange, United States , Orlando, United States and 4 more locations